Nephrology Conferences
Advertisement
Researchers studied the efficacy and safety of dapagliflozin in patients with chronic kidney disease stages 4 and 5.
A study examined whether the relationship between hyponatremia and higher mortality and rehospitalization is causal.
Researchers studied risk of postoperative AKI with perioperative hypotension- versus hypertension-avoidance strategies.
Carla Nester spoke about two presentations at Kidney Week focused on potential therapies for C3 glomerulopathy.
Sagar Nigwekar discussed interim data from the SEAPORT 1 trial of INZ-701 for treatment of calciphylaxis.
Guru Reddy discussed three posters presented by Unicycive Therapeutics at ASN Kidney Week 2024, on UNI-494 and OLC.
Benefits of empagliflozin continued for a period after discontinuation but were lesser and seemed temporary.
Jonathan Barratt discussed advances in IgA nephropathy treatment with Joel Topf at ASN Kidney Week 2024.
BTK inhibitor zanubrutinib was found to be well tolerated and showed activity in patients with membranous nephropathy.
Susan Quaggin, winner of the 2024 John P. Peters Award, spoke with us about the award, her work, and ASN Kidney Week.
Semaglutide reduced the risk of death among patients in the FLOW trial, who had CKD and type 2 diabetes.
Melissa Little discussed kidney regeneration and her stem cell research with Joel Topf of Nephrology Times.
Finerenone did not modify kidney outcomes but reduced albuminuria and risk of new-onset macroalbuminuria in patients with HF.
Mohamad Hussain spoke with us about a phase 3 trial of the acellular tissue engineered vessel in AV access for hemodialysis.
A trial assessed an acellular tissue engineered vessel (ATEV) compared to autologous arteriovenous fistula for hemodialysis.
After their poster tour at ASN Kidney Week 2024, Roger Rodby and Edgar Lerma shared a few highlights with Joel Topf.
Pegcetacoplan achieved significant reductions in proteinuria and C3c staining and stabilized eGFR in patients with C3G.
Katherine Tuttle spoke with Joel Topf about FLOW trial results presented at ASN Kidney Week 2024.
FLOW trial data showed semaglutide safely reduced risks of major kidney outcomes regardless of CKD severity.
Hiddo Heerspink discussed his Kidney Week presentations on SC0062 for IgAN and semaglutide in obesity with nondiabetic CKD.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.